Concepedia

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials

Alessandra Raimondi, Federico Nichetti, Arndt Stahler, Harpreet Wasan, Enrique Aranda, Giovanni Randon, Annika Kurreck, Angela Meade, Eduardo Díaz‐Rubio, Monica Niger,

European Journal of Cancer · 2023 · 12 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Andrés Cervantes, R. Adam, Susana Roselló et al. · Annals of Oncology · 2022 · 1.6K citations · Full text

, , +14

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text

, , +16

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

Christophe Tournigand, Andrés Cervantes, Arié Figer et al. · Journal of Clinical Oncology · 2006 · 805 citations

, , +15

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens, Harm van Tinteren, Anne M. May et al. · The Lancet · 2015 · 528 citations

, , +13

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 418 citations

, , +14